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Abstract: A new cyclic diamine, 1,5-diazacyclohenicosane (1), was isolated from samples 
of the marine sponge Mycale sp. collected at Lamu Island (Kenya). Its structure was 
determined by a combination of spectroscopic techniques, including (+)-HRESIMS and 1D 
and 2D NMR spectroscopy. The compound displayed cytotoxicity at the μM level against 
three human tumor cell lines. 
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1. Introduction 
Sponges continue to be a rich source of metabolites with interesting biological properties [1,2]. 
Among them, specimens belonging to the genus Mycale have been the subject of extensive research 
leading to the isolation and identification of a wide variety of novel structures. Some of these Mycale 
metabolites display interesting biological properties such as the antiviral and antitumour activities 
detected in the mycalamides [3,4], the potent cytotoxicity exhibited by the mycalolides [5–7], 
pateamine [8], and peloruside A [9] or the histone deacetylase inhibitory properties displayed by the 
cyclic tetrapeptides azumamides A-E [10]. 
As part of our continuing program to search for new anticancer agents, the chemical composition of 
samples of the marine sponge Mycale sp. collected at Lamu Island (Kenya) was investigated due to the 
cytotoxicity displayed by their organic extracts. Herein we report the isolation, structural 
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characterization and cytotoxic activity of a new cyclic diamine, 1,5-diazacyclohenicosane (1), obtained 
by bioassay-guided fractionation of extracts of this sponge. 
2. Results and Discussion  
Freshly collected samples of Mycale sp. were immediately frozen and transported stored in dry ice 
to PharmaMar. The frozen sponge was triturated and extracted with a 1:1 mixture of MeOH:CH2Cl2, 
and the organic extract subjected to reversed-phase VLC on Polygoprep C18 silica gel to yield a 
bioactive fraction containing compound 1 (Figure 1). 
Figure 1. Structure of compound 1. 
 
 
A pseudomolecular ion at m/z 297.3266 in the (+)-HRESIMS of 1 accounted for a molecular 
formula of C19H40N2 (calcd. for C19H41N2 297.3264), requiring one degree of unsaturation. The 
existence of an element of symmetry in the structure of the compound was evidenced by the presence 
of only nine resonance signals, one of them with double intensity, in its 
13C-NMR spectrum (Table 1). 
Only methylene groups were present in the structure of 1, according to the edited HSQC spectrum. The 
chemical shifts of two of the 
13C signals (48.2 and 45.2 ppm), accounting for four carbon atoms, 
indicated that these atoms were attached to nitrogen. COSY correlations measured in CD3OD  
(Table 1) established the presence of two spin systems in the molecule: from C-2 to C-4 and from C-6 
to C-21. Finally, key HMBC cross-peaks observed between H-2/H-4 and C-21/C-6, and between   
H-6/H-21 and C-4/C-2 (Figure 2) connected both spin systems and established the identity of 
compound 1 as 1,5-diazacyclohenicosane. 
The cytotoxic activity of 1 was tested against three human tumor cell lines, including lung (A549), 
colon (HT29) and breast (MDA-MB-231) tissues. The compound exhibited moderate activity with 
GI50 values in the micromolar range and no selectivity against the cell lines tested: 5.41 μM (A549), 
5.07 μM (HT29) and 5.74 μM (MDA-MB-231). Doxorubicin displayed values of 0.32 μM (A549), 
0.36 μM (HT29) and 0.26 μM (MDA-MB-231) when tested as a positive control under the same 
conditions. 
In summary, a new cytotoxic cyclic diamine, 1,5-diazacyclohenicosane (1), has been isolated from 
samples of the Kenyan sponge Mycale sp. Its structure resembles that of other cyclic amines 
previously characterized from sponge samples such as the motuporamines isolated from the Papua 
New Guinea sponge Xestospongia exigua [11-12] or halichlorensin obtained from South African 
specimens of Halichlona tulearensis [13-14]. This structural similarity together with the interesting 
anti-invasive and anti-angiogenic properties displayed by the motuporamine family suggest that further 
studies to assess the potential of our compound in this area of research are merited. Mar. Drugs 2009, 7                                    
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Table 1. NMR data of compound 1 (CD3OD, 500/75 MHz). 
Nº  δC, mult.  δH, mult. (J in Hz)  COSY  HMBC 
2 45.2,  CH2  3.20, t (7.2)  3  3, 4, 21 
3 23.3,  CH2  2.15, quint (7.2)  2, 4  2, 4 
4 45.2,  CH2  3.20, t (7.2)  3  2, 3, 6 
6 48.2,  CH2  3.06, m  7  4, 7, 8 
7 26.4,  CH2  1.76, m  6, 8  6, 8, 9 
8 26.9,  CH2  1.49, m  7, 9  6,7, 9, 10 
9 29.3,  CH2 1.39,  m     
10 29.1,  CH2 1.35,  m     
11 29.6,  CH2* 1.35,  m     
12 29.6,  CH2* 1.35,  m     
13 29.7,  CH2* 1.35,  m     
14 29.7,  CH2* 1.35,  m     
15 29.6,  CH2* 1.35,  m     
16 29.6,  CH2* 1.35,  m     
17 29.1,  CH2 1.35,  m     
18 29.3,  CH2 1.39,  m     
19 26.9,  CH2  1.49, m  18, 20  17, 18, 20, 21 
20 26.4,  CH2  1.76, m  19, 21  18, 19, 21 
21 48.2,  CH2  3.06, m  20  2, 19, 20 
* Interchangeable assignments. 
Figure 2. Key HMBC correlations for compound 1. 
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3. Experimental Section  
3.1. General 
NMR spectra were recorded on Varian “Unity 500” (500 MHz, 
1H) or Varian “Unity 300”   
(75 MHz, 
13C) spectrometers. Chemical shifts were reported in ppm using residual CD3OD (δ 3.31 for 
1H and 49.0 for 
13C) as internal reference. HMBC experiments were optimized for a 
3JCH of 8 Hz.  
(+)-HRESIMS was performed on a QSTAR Applied Biosystems spectrometer. (+)-ESIMS were 
recorded using an Agilent 1100 Series LC/MSD spectrometer.  
3.2. Animal material 
Mycale sp. was collected in August 2005 by SCUBA diving at depths between 8 and 24 m at Lamu 
Island (Kenya) (3º 37’ 07’’ S, 39º 53’ 43” E). The material was identified by Dr. José Luis Carballo 
from the Universidad Nacional Autónoma (México). A voucher specimen is deposited at PharmaMar 
(ORMA037245).  
3.3. Extraction and isolation 
The frozen organism (14 g) was triturated and extracted with a 1:1 mixture of CH2Cl2:MeOH  
(3 × 200 mL). The extract was concentrated to yield a crude of 1.20 g. This material was subjected to 
VLC on Polygoprep RP-18 with a stepped gradient from H2O:MeOH 3:1 to MeOH. The bioactive 
fraction eluted with H2O:MeOH 1:3 contained pure compound 1 (12.9 mg). 
1,5-Diazacyclohenicosane (1). Pale yellow amorphous solid; 
1H- (500 MHz) and 
13C-NMR (75 MHz) 
see Table 1; (+)-ESIMS m/z 297 [M+H]
+; (+)-HRESIMS m/z 297.3266 [M+H]
+ (calcd. for C19H41N2, 
297.3264). 
3.4. Biological activity 
A549 (ATCC CCL-185), lung carcinoma; HT29 (ATCC HTB-38), colorectal carcinoma and   
MDA-MB-231 (ATCC HTB-26), breast adenocarcinoma cell lines were obtained from the ATCC. 
Cell lines were maintained in RPMI medium supplemented with 10% fetal calf serum (FCS), 2 mM  
L-glutamine and 100 U/mL penicillin and streptomycin, at 37 ºC and 5% CO2. Triplicate cultures were 
incubated for 72 h in the presence or absence of test compounds (at ten concentrations ranging from  
10 to 0.0026 μg/mL). For quantitative estimation of cytotoxicity, the colorimetric sulforhodamine B 
(SRB) method was used [15]. Briefly, cells were washed twice with PBS, fixed for 15 min in   
1% glutaraldehyde solution, rinsed twice in PBS, and stained in 0.4% SRB solution for 30 min at room 
temperature. Cells were then rinsed several times with 1% acetic acid solution and air-dried. 
Sulforhodamine B was then extracted in 10 mM trizma base solution and the absorbance measured at 
490 nm. Results are expressed as GI50, the concentration that causes 50% inhibition in cell growth 
after correction for cell count at the start of the experiment (NCI algorithm). Doxorubicin and DMSO 
(solvent) were used as the positive and negative controls in this assay. Prism 3.03 from GraphPad was 
used for the statistical analysis of the cell growth inhibition results. Mar. Drugs 2009, 7                                    
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